Ben Sessa, Laurie Higbed, David Nutt. Front Psychiatry 2019
Times Cited: 41
Times Cited: 41
Times Cited
Times Co-cited
Similarity
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Michael C Mithoefer, Allison A Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin. Psychopharmacology (Berl) 2019
Michael C Mithoefer, Allison A Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin. Psychopharmacology (Berl) 2019
39
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Jennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot'alora G, Wael Garas, Casey Paleos, Ingmar Gorman,[...]. Nat Med 2021
Jennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot'alora G, Wael Garas, Casey Paleos, Ingmar Gorman,[...]. Nat Med 2021
34
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer, Lisa Jerome, Rick Doblin. J Psychopharmacol 2011
Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer, Lisa Jerome, Rick Doblin. J Psychopharmacol 2011
29
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst. J Psychopharmacol 2016
Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst. J Psychopharmacol 2016
29
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Michael C Mithoefer, Ann T Mithoefer, Allison A Feduccia, Lisa Jerome, Mark Wagner, Joy Wymer, Julie Holland, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson,[...]. Lancet Psychiatry 2018
Michael C Mithoefer, Ann T Mithoefer, Allison A Feduccia, Lisa Jerome, Mark Wagner, Joy Wymer, Julie Holland, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson,[...]. Lancet Psychiatry 2018
29
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding,[...]. Lancet Psychiatry 2016
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding,[...]. Lancet Psychiatry 2016
26
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb,[...]. J Psychopharmacol 2016
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb,[...]. J Psychopharmacol 2016
26
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.
Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer, Lisa Jerome, Scott F Martin, Berra Yazar-Klosinski, Yvonne Michel, Timothy D Brewerton, Rick Doblin. J Psychopharmacol 2013
Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer, Lisa Jerome, Scott F Martin, Berra Yazar-Klosinski, Yvonne Michel, Timothy D Brewerton, Rick Doblin. J Psychopharmacol 2013
26
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
Alicia L Danforth, Charles S Grob, Christopher Struble, Allison A Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson. Psychopharmacology (Berl) 2018
Alicia L Danforth, Charles S Grob, Christopher Struble, Allison A Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson. Psychopharmacology (Berl) 2018
24
The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.
Philip Kamilar-Britt, Gillinder Bedi. Neurosci Biobehav Rev 2015
Philip Kamilar-Britt, Gillinder Bedi. Neurosci Biobehav Rev 2015
21
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
Leor Roseman, David J Nutt, Robin L Carhart-Harris. Front Pharmacol 2018
Leor Roseman, David J Nutt, Robin L Carhart-Harris. Front Pharmacol 2018
21
MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?
Allison A Feduccia, Michael C Mithoefer. Prog Neuropsychopharmacol Biol Psychiatry 2018
Allison A Feduccia, Michael C Mithoefer. Prog Neuropsychopharmacol Biol Psychiatry 2018
21
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer. Arch Gen Psychiatry 2011
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer. Arch Gen Psychiatry 2011
21
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, Rudolf Brenneisen. J Nerv Ment Dis 2014
Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, Rudolf Brenneisen. J Nerv Ment Dis 2014
21
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, P C R Barbosa, Rick J Strassman. J Psychopharmacol 2015
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, P C R Barbosa, Rick J Strassman. J Psychopharmacol 2015
21
A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).
Peter Oehen, Rafael Traber, Verena Widmer, Ulrich Schnyder. J Psychopharmacol 2013
Peter Oehen, Rafael Traber, Verena Widmer, Ulrich Schnyder. J Psychopharmacol 2013
19
Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.
Lukasz Smigielski, Milan Scheidegger, Michael Kometer, Franz X Vollenweider. Neuroimage 2019
Lukasz Smigielski, Milan Scheidegger, Michael Kometer, Franz X Vollenweider. Neuroimage 2019
19
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
Katherine A MacLean, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2011
Katherine A MacLean, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2011
19
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Francisco A Moreno, Christopher B Wiegand, E Keolani Taitano, Pedro L Delgado. J Clin Psychiatry 2006
Francisco A Moreno, Christopher B Wiegand, E Keolani Taitano, Pedro L Delgado. J Clin Psychiatry 2006
19
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano, Roland R Griffiths. J Psychopharmacol 2014
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano, Roland R Griffiths. J Psychopharmacol 2014
19
Human hallucinogen research: guidelines for safety.
Mw Johnson, Wa Richards, Rr Griffiths. J Psychopharmacol 2008
Mw Johnson, Wa Richards, Rr Griffiths. J Psychopharmacol 2008
19
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
R R Griffiths, W A Richards, U McCann, R Jesse. Psychopharmacology (Berl) 2006
R R Griffiths, W A Richards, U McCann, R Jesse. Psychopharmacology (Berl) 2006
19
MDMA enhances emotional empathy and prosocial behavior.
Cédric M Hysek, Yasmin Schmid, Linda D Simmler, Gregor Domes, Markus Heinrichs, Christoph Eisenegger, Katrin H Preller, Boris B Quednow, Matthias E Liechti. Soc Cogn Affect Neurosci 2014
Cédric M Hysek, Yasmin Schmid, Linda D Simmler, Gregor Domes, Markus Heinrichs, Christoph Eisenegger, Katrin H Preller, Boris B Quednow, Matthias E Liechti. Soc Cogn Affect Neurosci 2014
17
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling,[...]. Psychopharmacology (Berl) 2018
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling,[...]. Psychopharmacology (Berl) 2018
17
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst. J Psychopharmacol 2018
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst. J Psychopharmacol 2018
17
Effects of Schedule I drug laws on neuroscience research and treatment innovation.
David J Nutt, Leslie A King, David E Nichols. Nat Rev Neurosci 2013
David J Nutt, Leslie A King, David E Nichols. Nat Rev Neurosci 2013
17
Subjective reports of the effects of MDMA in a clinical setting.
G Greer, R Tolbert. J Psychoactive Drugs 1986
G Greer, R Tolbert. J Psychoactive Drugs 1986
17
Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
Tomislav Majić, Timo T Schmidt, Jürgen Gallinat. J Psychopharmacol 2015
Tomislav Majić, Timo T Schmidt, Jürgen Gallinat. J Psychopharmacol 2015
14
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Theresa M Carbonaro, Matthew P Bradstreet, Frederick S Barrett, Katherine A MacLean, Robert Jesse, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2016
Theresa M Carbonaro, Matthew P Bradstreet, Frederick S Barrett, Katherine A MacLean, Robert Jesse, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2016
14
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.
R L Carhart-Harris, K J Friston. Pharmacol Rev 2019
R L Carhart-Harris, K J Friston. Pharmacol Rev 2019
14
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.
Peter Gasser, Katharina Kirchner, Torsten Passie. J Psychopharmacol 2015
Peter Gasser, Katharina Kirchner, Torsten Passie. J Psychopharmacol 2015
14
Predicting Responses to Psychedelics: A Prospective Study.
Eline C H M Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E Daws, Adam D G Hampshire, Romy Lorenz,[...]. Front Pharmacol 2018
Eline C H M Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E Daws, Adam D G Hampshire, Romy Lorenz,[...]. Front Pharmacol 2018
14
Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.
G J H Dumont, F C G J Sweep, R van der Steen, R Hermsen, A R T Donders, D J Touw, J M A van Gerven, J K Buitelaar, R J Verkes. Soc Neurosci 2009
G J H Dumont, F C G J Sweep, R van der Steen, R Hermsen, A R T Donders, D J Touw, J M A van Gerven, J K Buitelaar, R J Verkes. Soc Neurosci 2009
14
Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.
Sascha B Thal, Miriam J J Lommen. J Contemp Psychother 2018
Sascha B Thal, Miriam J J Lommen. J Contemp Psychother 2018
31
MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics".
Ben Sessa. Neurosci Lett 2017
Ben Sessa. Neurosci Lett 2017
14
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
Robin L Carhart-Harris, Guy M Goodwin. Neuropsychopharmacology 2017
Robin L Carhart-Harris, Guy M Goodwin. Neuropsychopharmacology 2017
14
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.
Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy,[...]. Sci Rep 2017
Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy,[...]. Sci Rep 2017
14
Psychedelics Promote Structural and Functional Neural Plasticity.
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
14
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
Rr Griffiths, Wa Richards, Mw Johnson, Ud McCann, R Jesse. J Psychopharmacol 2008
Rr Griffiths, Wa Richards, Mw Johnson, Ud McCann, R Jesse. J Psychopharmacol 2008
14
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C Andrade, Morgana M Novaes, Jessica A Pessoa, Sergio A Mota-Rolim, Flávia L Osório, Rafael Sanches, Rafael G Dos Santos,[...]. Psychol Med 2019
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C Andrade, Morgana M Novaes, Jessica A Pessoa, Sergio A Mota-Rolim, Flávia L Osório, Rafael Sanches, Rafael G Dos Santos,[...]. Psychol Med 2019
12
The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.
Katrin H Preller, Marcus Herdener, Thomas Pokorny, Amanda Planzer, Rainer Kraehenmann, Philipp Stämpfli, Matthias E Liechti, Erich Seifritz, Franz X Vollenweider. Curr Biol 2017
Katrin H Preller, Marcus Herdener, Thomas Pokorny, Amanda Planzer, Rainer Kraehenmann, Philipp Stämpfli, Matthias E Liechti, Erich Seifritz, Franz X Vollenweider. Curr Biol 2017
12
Effects of psilocybin therapy on personality structure.
D Erritzoe, L Roseman, M M Nour, K MacLean, M Kaelen, D J Nutt, R L Carhart-Harris. Acta Psychiatr Scand 2018
D Erritzoe, L Roseman, M M Nour, K MacLean, M Kaelen, D J Nutt, R L Carhart-Harris. Acta Psychiatr Scand 2018
12
The paradoxical psychological effects of lysergic acid diethylamide (LSD).
R L Carhart-Harris, M Kaelen, M Bolstridge, T M Williams, L T Williams, R Underwood, A Feilding, D J Nutt. Psychol Med 2016
R L Carhart-Harris, M Kaelen, M Bolstridge, T M Williams, L T Williams, R Underwood, A Feilding, D J Nutt. Psychol Med 2016
12
Psychedelics and connectedness.
R L Carhart-Harris, D Erritzoe, E Haijen, M Kaelen, R Watts. Psychopharmacology (Berl) 2018
R L Carhart-Harris, D Erritzoe, E Haijen, M Kaelen, R Watts. Psychopharmacology (Berl) 2018
12
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
Michael C Mithoefer, Charles S Grob, Timothy D Brewerton. Lancet Psychiatry 2016
Michael C Mithoefer, Charles S Grob, Timothy D Brewerton. Lancet Psychiatry 2016
12
12
14
Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects.
Patrick C Dolder, Felix Müller, Yasmin Schmid, Stefan J Borgwardt, Matthias E Liechti. Psychopharmacology (Berl) 2018
Patrick C Dolder, Felix Müller, Yasmin Schmid, Stefan J Borgwardt, Matthias E Liechti. Psychopharmacology (Berl) 2018
12
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.
Marcela Ot'alora G, Jim Grigsby, Bruce Poulter, Joseph W Van Derveer, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson,[...]. J Psychopharmacol 2018
Marcela Ot'alora G, Jim Grigsby, Bruce Poulter, Joseph W Van Derveer, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson,[...]. J Psychopharmacol 2018
12
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.